Amplifon stock rises as TIME accolade meets solid earnings backdrop

Published on 09/10/2026 at 18:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amplifon stock edged higher on Borsa Italiana around EUR 11.40 on September 10, 2026 after being named among TIME’s best companies worldwide. The hearing-care group’s H1 2026 revenue and margin trends give investors context for the move.

Modernes Hörzentrum mit Beratungsraum und Hörgeräte-Ausstellung, fotorealistisch — Fotorealistisches Bild zeigt modernen Hörzentrum-Ladenraum, passend zu Amplifon S.p.A. mit ISIN IT0004056880, Sektor Medizintechnik, Illustration mit AI erstellt.

Amplifon stock (ISIN IT0004056880) traded around EUR 11.40 on Borsa Italiana on September 10, 2026, with intraday data showing a last trade at EUR 11.40 and a modest gain of 0.93% during the afternoon session. As Italian market portal Borsa Italiana reported with a 16:26:11 timestamp on September 10, 2026, the shares moved in a daily range between EUR 11.205 and EUR 11.42, starting from an opening price of EUR 11.225.

TIME recognition and recent share performance

According to Teleborsa on September 10, 2026, Amplifon was cited among the world’s best companies in 2026 in a ranking compiled by TIME Magazine, highlighting the group’s positioning in global hearing-health services. The news came as the stock was quoted at EUR 11.40 on Borsa Italiana during the afternoon, up 0.93% on the day in the Teleborsa snapshot, and helped underpin sentiment after a weaker prior close.

Price data from Borsa Italiana’s end-of-day tables show that Amplifon closed at EUR 11.295 on September 9, 2026, representing a decline of 2.21% versus the previous session and marking a clear pullback within its recent trading band. The same overview indicates an intraday low of EUR 11.525 and a closing print at 17:35:22, situating the current EUR 11.40 area slightly above that prior close and illustrating how the TIME-related recognition has coincided with a partial recovery.

Latest price levels and market capitalization

Borsa Italiana’s FTSE MIB performance page lists Amplifon with a last value around EUR 11.25 on September 10, 2026, versus a price at EUR 11.295 used for daily percentage calculations and a move of approximately minus 0.40% in that specific snapshot, underscoring how intraday readings can differ depending on the exact time captured. The more granular Teleborsa quote at 16:26:11 shows the stock at EUR 11.40 with a positive 0.93% change, meaning investors saw the shares oscillate in a relatively tight range around the EUR 11.30 reference from the previous close.

From a broader valuation perspective, a capitalisation table for Piazza Affari from Il Sole 24 Ore lists Amplifon with a market capitalization of EUR 4,533 million, providing a sense of scale for the mid-cap hearing-care specialist. This context matters for investors comparing Amplifon to peers in medtech and consumer-health segments, as it signals that the company has meaningful size but remains more nimble than the largest global healthcare names.

Fundamentals and recent earnings trajectory

While the week-filtered sources focus on price and recognition, Amplifon’s fundamental profile is shaped by its most recent half-year and full-year results published earlier in 2026 and late 2025. According to the investor-relations materials from Amplifon, the group’s latest reported fiscal-year and interim figures show continued revenue growth and solid profitability from its global retail network of hearing-aid centers, although the precise numbers and margins are detailed in reports issued before September 3, 2026 and thus only serve as historical context here. In those filings, Amplifon typically presents revenue, recurring EBITDA and adjusted net profit trends by region, reflecting its expansion in Europe, North America and Asia-Pacific.

Historical comparisons in Italian financial media note that Amplifon has in recent years grown its revenue base by low-to-mid double-digit percentages, supported by acquisitions and organic expansion of its store footprint. For example, prior-year capitalisation tables and consensus overviews referenced by Il Sole 24 Ore indicate a prevailing BUY recommendation on the shares alongside the EUR 4,533 million market cap figure, suggesting that analysts historically have viewed the company’s earnings growth as supportive for the valuation.

Analyst stance and hearing-health sector context

The analyst insights section on Yahoo Finance for the AMP.MI ticker highlights a range of analyst recommendations from Strong Buy through Sell and displays an average target price of EUR 13.53 against a current quote around EUR 11.31, with a high target at EUR 16.70. Although the latest individually named rating action in that overview dates back to 2021, the aggregate target data provide a quantified comparison: the average target of EUR 13.53 stands about EUR 2.22 above the recent EUR 11.31 quote, implying potential upside in analysts’ models relative to the current share price.

In the broader hearing-health and medtech sector, recent market wrap commentary cited by specialist outlets has pointed to mixed trading in hearing-aid manufacturers and retailers amid macroeconomic uncertainty and shifting reimbursement landscapes. Sector snapshots for European medtech compiled during early September 2026 show that Amplifon’s share performance has occasionally lagged more diversified healthcare players, with intraday declines such as the 2.21% drop on September 9, 2026 underscoring sensitivity to risk-off moves even as fundamentals remain underpinned by demographic trends.

Stock positioning for investors

As of the latest available intraday data on September 10, 2026, Amplifon stock’s reference level of EUR 11.40 on Borsa Italiana sits modestly above the previous closing price of EUR 11.295 from September 9, 2026, suggesting that the TIME Magazine recognition has coincided with a small rebound from the prior session’s decline. With a market capitalization of around EUR 4,533 million and analyst consensus targets clustered above the current trading band, the shares remain positioned as a mid-cap growth play in global hearing care, offering investors exposure to aging-population dynamics but also to volatility tied to consumer demand and healthcare-policy developments.